HIF1A and ovarian cancer: In conclusion, we suggest that the mechanism behind GP‐2250's anti‐neoplastic effect on ovarian cancer cells includes inhibition of glycolysis via modulation of HK2 activation and expression and inhibition of HIF‐1α induced VEGF secretion.